<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04725136</url>
  </required_header>
  <id_info>
    <org_study_id>K0104</org_study_id>
    <nct_id>NCT04725136</nct_id>
  </id_info>
  <brief_title>Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis</brief_title>
  <official_title>A Phase I/IIa Clinical Trial to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kang Stem Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kang Stem Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I/IIa Clinical Trial to Evaluate the Safety and Explore the Efficacy of Multiple&#xD;
      Doses of FURESTEM-AD inj. for Moderate to Severe Chronic Atopic Dermatitis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1: Multicenter, repeated administration, disclosure, dose escalation, Evaluate safety&#xD;
      and tolerability and explore efficacy&#xD;
&#xD;
      Phase 2a: Multicenter, repeated administration, random assignment, double blinding, parallel,&#xD;
      Efficacy and safety are evaluated for repeated administration compared to placebo and single&#xD;
      administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">January 31, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>24 weeks follow-up after first treatment</time_frame>
    <description>safety information including drug tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose EASI decreased by 50% or more at each evaluation visit compared to the baseline (EASI-50)</measure>
    <time_frame>24 weeks follow-up after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose Eczema Area and Severity Index (EASI) was decreased from baseline by more than 75% at each visit (EASI-75)</measure>
    <time_frame>24 weeks follow-up after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change and Change in EASI from baseline</measure>
    <time_frame>24 weeks follow-up after first treatment</time_frame>
    <description>EASI range is from 0 (clear) to 72 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose Investigator's Global Assessment (IGA) score at each visit is 0 or 1</measure>
    <time_frame>24 weeks follow-up after first treatment</time_frame>
    <description>IGA score is from 0 (clear) to 5 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose IGA at each visit is 0 or 1, or improved to 2 or higher</measure>
    <time_frame>24 weeks follow-up after first treatment</time_frame>
    <description>IGA score is from 0 (clear) to 5 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects whose SCORing Atopic Dermatitis (SCORAD) INDEX was decreased from baseline by more than 50% at each visit (SCORAD-50)</measure>
    <time_frame>24 weeks follow-up after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change and Change in SCORAD index from baseline at each visit</measure>
    <time_frame>24 weeks follow-up after first treatment</time_frame>
    <description>SCORAD index range is from 0 (clear) to 103 (severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and rate of change in Body Surface Area (BSA)</measure>
    <time_frame>24 weeks follow-up after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and rate of change in total serum Immunoglobulin E (IgE)</measure>
    <time_frame>24 weeks follow-up after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and rate of change in Cytokine</measure>
    <time_frame>24 weeks follow-up after first treatment</time_frame>
    <description>CCL17(TARC), CCL18(PARC), CCL26(eotaxin-3), CCL27(CTACK), IL-4, IL-17A, IL-22, SCCA2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and rate of change DLQI</measure>
    <time_frame>24 weeks follow-up after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and rate of change POEM</measure>
    <time_frame>24 weeks follow-up after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and rate of change Peak Pruritus NRS</measure>
    <time_frame>24 weeks follow-up after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change and rate of change eosinophil</measure>
    <time_frame>24 weeks follow-up after first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use the number and total amount of rescue</measure>
    <time_frame>24 weeks follow-up after first treatment</time_frame>
    <description>only Phase 2a</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>High-dose repeat administration group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FURESTEM-AD Inj 1.0 x 10^8 cells /body 3 repeated subcutaneous injection at 4 week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose single administration group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FURESTEM-AD Inj 1.0 x 10^8 cells /body 1 single subcutaneous injection, and Placebo 2 repeated subcutaneous injection at 4 week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose repeat administration group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FURESTEM-AD Inj 5.0 x 10^7 cells /body 3 repeated subcutaneous injection at 4 week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose single administration group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FURESTEM-AD Inj 5.0 x 10^7 cells /body 1 single subcutaneous injection, and Placebo 2 repeated subcutaneous injection at 4 week intervals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline(0.9% NaCl) 3 repeated subcutaneous injection at 4 week intervals</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FURESTEM-AD inj</intervention_name>
    <description>Repeated administration group: 3 times high or low dose at 4 week intervals. Single administration group: 1 time high or low dose, 2 times placebo injection at 4 week intervals Placebo: 3 times placebo injection at 4 week intervals.</description>
    <arm_group_label>High-dose repeat administration group</arm_group_label>
    <arm_group_label>High-dose single administration group</arm_group_label>
    <arm_group_label>Low-dose repeat administration group</arm_group_label>
    <arm_group_label>Low-dose single administration group</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Of either gender, aged &gt;=19&#xD;
&#xD;
          2. Atopic Dermatitis subjects who are coincident with Hanifin and Rajka diagnosis&#xD;
             criteria&#xD;
&#xD;
          3. Chronic Atopic Dermatitis that has been present for at least 3 years&#xD;
&#xD;
          4. EASI&gt;=16 at screening and baseline visit&#xD;
&#xD;
          5. IGA&gt;=3, SCORAD index&gt;=25, BSA &gt;=10% of AD involvement at screegning and baseline visit&#xD;
&#xD;
          6. Subjects with documented record of inadequate response to the stable use of topical&#xD;
             atopic dermatitis treatment within 24 weeks before participating in the study, or whom&#xD;
             are inadvisable due to safety risks&#xD;
&#xD;
          7. Subjects who understand and voluntarily sign an informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with medical history or surgery/procedure history&#xD;
&#xD;
          2. Subjects with diseases at the time of participation in this study (systemic infection,&#xD;
             other serious skin disorders, pigmentation or extensive scarring in atopic dermatitis&#xD;
             symptom region)&#xD;
&#xD;
          3. Renal dysfunction with creatinine &gt;2.0 mg/dL at screening&#xD;
&#xD;
          4. Hepatic dysfunction with ALT or AST levels 2.5 times higher than the normal range at&#xD;
             screening&#xD;
&#xD;
          5. ALC&lt;800/mm3 at screening&#xD;
&#xD;
          6. Subjects with live vaccine administration within 12 weeks before baseline&#xD;
&#xD;
          7. Receipt of leukotriene receptor antagonists, systemic steroids, systemic or topical&#xD;
             antihistamines, phototherapy, or systemic immunosuppressants/modulators including&#xD;
             janus kinase (JAK) inhibitors, and/or any other systemic therapy within 4 weeks before&#xD;
             Baseline&#xD;
&#xD;
          8. Receipt of topical steroids(class1~6), topical tacrolimus or pimecrolimus within 2&#xD;
             weeks before Baseline&#xD;
&#xD;
          9. Subjects who need prohibited medication during clinical period&#xD;
&#xD;
         10. Pregnant, breast-feeding women or women who plan to become pregnant during this study&#xD;
&#xD;
         11. Subjects who currently participate in other clinical trial or participated in other&#xD;
             clinical trial within 4 weeks&#xD;
&#xD;
         12. Subjects with experience of administering FURESTEM-AD inj.&#xD;
&#xD;
         13. Any other condition which the investigator judges would make patient unsuitable for&#xD;
             study participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dongguk University Medical Center</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hUCB-MSC</keyword>
  <keyword>Atopic Dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

